EGI
PDSB icon

EAM Global Investors’s PDS Biotechnology PDSB Stock Holding History

EAM Global Investors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-122,306
Closed -$1.61M – 162
2022
Q4 		$1.61M Buy
+122,306
New +$863K 0.42% 124
2021
Q4 		– Sell
-158,637
Closed -$2.36M – 246
2021
Q3 		$2.36M Sell
158,637
-29,263
-16% -$365K 0.56% 63
2021
Q2 		$2.36M Buy
+187,900
New +$1.47M 0.65% 68

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Global Investors's PDSB Position: Q1 2023 in Review

EAM Global Investors sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 122,306 shares — an estimated $1.61M sold.

EAM Global Investors first reported a position in PDSB in Q2 2021 and held it in 3 quarters. The position peaked at $2.36M in Q3 2021. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • EAM Global Investors reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 122,306 PDS Biotechnology shares in Q1 2023, an estimated $1.61M.
  • EAM Global Investors first reported a position in PDS Biotechnology in Q2 2021 and held it in 3 quarters.
  • EAM Global Investors's PDS Biotechnology position peaked at $2.36M in Q3 2021.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.